Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Debt (2020 - 2024)

Bicycle Therapeutics' Total Debt history spans 5 years, with the latest figure at $30.9 million for Q2 2024.

  • For Q2 2024, Total Debt rose 1.3% year-over-year to $30.9 million; the TTM value through Jun 2024 reached $30.9 million, up 1.3%, while the annual FY2023 figure was $30.7 million, 1.26% up from the prior year.
  • Total Debt reached $30.9 million in Q2 2024 per BCYC's latest filing, roughly flat from $30.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $30.9 million in Q2 2024 to a low of $14.4 million in Q3 2020.
  • Average Total Debt over 5 years is $28.3 million, with a median of $30.2 million recorded in 2022.
  • Peak YoY movement for Total Debt: skyrocketed 106.23% in 2021, then increased 1.22% in 2023.
  • A 5-year view of Total Debt shows it stood at $14.5 million in 2020, then soared by 105.95% to $29.9 million in 2021, then increased by 1.48% to $30.3 million in 2022, then rose by 1.26% to $30.7 million in 2023, then grew by 0.69% to $30.9 million in 2024.
  • Per Business Quant, the three most recent readings for BCYC's Total Debt are $30.9 million (Q2 2024), $30.8 million (Q1 2024), and $30.7 million (Q4 2023).